[7]Bartsch R, Berghoff AS, Furtner J, et al. Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial. Nat Med. 2022 Aug 8. [8]Pérez-García JM, Batista MV, Cortez P, et al. Trastuzumab Deruxtecan in Patients with Central Nervous Sys...
[12]Giuliani S, Ciniselli CM, Leonardi E, Polla E, Decarli N, Luchini C, et al.. In a cohort of breast cancer screened patients the proportion of HER2 positive cases is lower than that earlier reported and patholog...
[2]Paracha N, Reyes A, Diéras V, et al. Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-po...
[5]Tolaney SM,Tarantino P,Graham N,et al.Adjuvant paclitaxel and trastuzumab for node-negative,HER2-positive breast cancer:final 10-year analysis of the open-label,single-arm,phase 2 APT trial.Lancet Oncol.2023 Mar;24(3):273-285. [6]Tolaney SM,Barry WT,Dang CT,et al.Adjuvant paclitaxe...
[2] Gianni, L. et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2 positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol. 15, 640–647 (2014).[3] Wu, J. et al. Neoadjuvant ...
[2] Gianni, L. et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2 positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol. 15, 640–647 (2014). ...
in this trial — a middle-aged woman with metastatic HER2-positive breast cancer in bone, liver, and lung that had progressed on every chemotherapy then known to have activity in the disease. She had a nearly miraculous response, with complete resolution of her pulmonary and hepatic metastases ...
11.Krop IE, LoRusso P, Miller KD, Modi S, Yardley D, Rodriguez G, et al. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane,...
Our study should be viewed in the context of two other trials.The Japanese TRIGGER trial demonstrated a survival benefit of trastuzumab for patients with HER2-positive gastric cancer and limited lymph node metastases.Additionally,the HER-FLOT trial,led by Ralf Hofheinz,reported an impressive three-ye...
[2] Gianni, L. et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2 positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. ...